ENTRY       D08879                      Drug
NAME        Brivaracetam (JAN/USAN/INN);
            Briviact (TN)
PRODUCT     BRIVIACT (UCB)
FORMULA     C11H20N2O2
EXACT_MASS  212.1525
MOL_WEIGHT  212.2887
CLASS       Neuropsychiatric agent
             DG03199  Antiepileptic agent
              DG02038  Piracetam antiepileptic
            Metabolizing enzyme substrate
             DG01639  CYP2C19 substrate
REMARK      ATC code: N03AX23
            Product: D08879<US>
EFFICACY    Anticonvulsant, Pain relief
COMMENT     Levetiracetam [DR:D00709] derivative
            Treatment of epilepsy, neuropathic pain and essential tremor
TARGET      SV2A [HSA:9900] [KO:K06258]
  PATHWAY   hsa04512(9900)  ECM-receptor interaction
METABOLISM  Enzyme: CYP2C19 [HSA:1557]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N03 ANTIEPILEPTICS
               N03A ANTIEPILEPTICS
                N03AX Other antiepileptics
                 N03AX23 Brivaracetam
                  D08879  Brivaracetam (JAN/USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Anticonvulsants
              Anticonvulsants, Other
               Brivaracetam
                D08879  Brivaracetam (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG03199  Antiepileptic agent
               DG02038  Piracetam antiepileptic
                D08879  Brivaracetam
             Metabolizing enzyme substrate
              DG01639  CYP2C19 substrate
               D08879  Brivaracetam
            Drug classes [BR:br08332]
             Neuropsychiatric agent
              DG03199  Antiepileptic agent
               D08879  Brivaracetam
            Target-based classification of drugs [BR:br08310]
             Transporters
              Major facilitator superfamily
               VNT family
                SV2A
                 D08879  Brivaracetam (JAN/USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D08879
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D08879
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D08879
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D08879
            Pharmacogenomic biomarkers [br08341.html]
             Polymorphisms and mutations affecting drug response
              D08879
DBLINKS     CAS: 357336-20-0
            PubChem: 96025562
            ChEBI: 133013
            LigandBox: D08879
ATOM        15
            1   N1y N    29.4350  -21.8855
            2   C1c C    30.6233  -21.1865
            3   C5x C    28.2467  -21.0467
            4   C1x C    28.9457  -23.2136
            5   C5a C    31.8117  -21.8855
            6   C1x C    27.1283  -21.8855
            7   O5x O    28.2467  -19.6487
            8   C1y C    27.5477  -23.2136
            9   N1a N    33.0000  -21.1865
            10  O5a O    31.8117  -23.2835
            11  C1b C    26.7213  -24.3412
            12  C1b C    25.3184  -24.1880
            13  C1a C    24.4873  -25.3220
            14  C1b C    30.6233  -19.7885
            15  C1a C    31.8340  -19.0895
BOND        15
            1     1   2 1
            2     1   3 1
            3     1   4 1
            4     2   5 1
            5     3   6 1
            6     3   7 2
            7     4   8 1
            8     5   9 1
            9     5  10 2
            10    6   8 1
            11    8  11 1 #Down
            12   11  12 1
            13   12  13 1
            14    2  14 1 #Up
            15   14  15 1
///
